发明名称 |
4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
摘要 |
The present invention relates to 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone tosylate salt in crystalline and in solid forms, the method of making and using such crystals. |
申请公布号 |
US9199995(B2) |
申请公布日期 |
2015.12.01 |
申请号 |
US201414177689 |
申请日期 |
2014.02.11 |
申请人 |
INTRA-CELLULAR THERAPIES, INC. |
发明人 |
Tomesch John;Wennogle Lawrence P. |
分类号 |
C07D471/22;C07D471/16;C07C309/30 |
主分类号 |
C07D471/22 |
代理机构 |
Hoxie & Associates LLC |
代理人 |
Hoxie & Associates LLC |
主权项 |
1. A method for modulating 5-hydroxytryptamine 2 receptor activity in a patient, comprising administering to a patient in need thereof an effective amount of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′: 4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal, wherein said salt crystal exhibits an X-ray powder diffraction pattern comprising at least two peaks having 2-theta values selected from the group consisting of 5.68°, 12.11°, 16.04°, 17.03°, 18.16°, 19.00°, 21.67°, 22.55°, 23.48° and 24.30°, wherein the X-ray powder diffraction data is collected on a diffractometer operating with a copper anode with a nickel filter. |
地址 |
New York NY US |